Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that it has signed an agreement to acquire the DNA and RNA business of Officinae Bio. The acquisition is expected to expand Maravai and TriLink BioTechnologies’ ability to assist customers in developing innovative nucleic acid-based therapies. Based in Venice, Italy, Officinae Bio is a privately held technology company with a proprietary digital platform to support the biological design of therapeutics.
Read the full article: Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research //
Source: https://www.businesswire.com/news/home/20241107589983/en/Maravai-LifeSciences-Plans-to-Acquire-DNA-and-RNA-Business-of-Officinae-Bio-Advancing-Support-for-Innovative-Nucleic-Acid-Research